SHERIDAN, WYOMING – November 10, 2024 – Cardinal Health (NYSE: CAH) today reported strong first quarter fiscal year 2025 results, with non-GAAP operating earnings increasing 12% to $625 million and non-GAAP diluted EPS increasing 9% to $1.88. The company also raised its fiscal year 2025 non-GAAP EPS guidance to $7.75 to $7.90, from $7.55 to $7.70.“We began fiscal 2025 by delivering strong operational and financial performance, led by the Pharmaceutical and Specialty Solutions segment,” said Jason Hollar, CEO of Cardinal Health. “The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year. Across the business, we remain focused on executing our plan to best serve our customers and create value for our shareholders.”
First Quarter Fiscal Year 2025 Financial Highlights Revenue decreased 4% to $52.3 billion; revenue increased 15% excluding the impact of the previously communicated large customer contract expiration
GAAP operating earnings were $568 million; GAAP diluted EPS was $1.70
Non-GAAP operating earnings increased 12% to $625 million, driven by significant growth in Pharmaceutical and Specialty Solutions segment profit
Non-GAAP diluted EPS increased 9% to $1.88
Segment Results
Pharmaceutical and Specialty Solutions segment revenue decreased 5% to $48.0 billion; revenue increased 16% excluding the impact of the customer contract expiration, driven by brand and specialty pharmaceutical sales growth from existing customers.
Pharmaceutical and Specialty Solutions segment profit increased 16% to $530 million in the first quarter, driven by a higher contribution from brand and specialty products, including the earlier seasonal launch of COVID-19 vaccine distribution, and positive generics program performance. This growth was partially offset by the customer contract expiration.
Global Medical Products and Distribution segment revenue increased 3% to $3.1 billion, driven by volume growth from existing customers.
Global Medical Products and Distribution segment profit decreased to $8 million in the first quarter, primarily due to higher manufacturing and health and welfare costs, largely offset by an improvement in net inflationary impacts, including mitigation initiatives, and growth from existing customers.
Other
Revenue increased 13% to $1.2 billion, driven by growth across the three operating segments: at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight Logistics.
Segment profit increased 8% to $104 million in the first quarter, driven by the performance of OptiFreight Logistics.
Fiscal Year 2025 Outlook
The company raised its fiscal 2025 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $7.75 to $7.90, from $7.55 to $7.70.
This guidance includes an update to the company’s Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, from 1% to 3% growth. The company also updated its Global Medical Products and Distribution segment profit outlook to $140 million to $175 million, from approximately $175 million, primarily due to the impact of higher health and welfare costs. Additionally, the company updated expectations for its adjusted free cash flow to $1.0 billion to $1.5 billion, from approximately $1.0 billion.
Recent Highlights
Cardinal Health announced in September that the company entered into a definitive agreement to acquire Integrated Oncology Network (ION), a physician-led independent community oncology network, for $1.1B in cash. The acquisition accelerates the development of Navista oncology alliance, providing additional capabilities supporting independent community practices and adding more than 100 providers delivering broad-reaching oncology and urology care across 10 states.
Cardinal Health initiated a $375M accelerated share repurchase program in the first quarter, which was completed in October
Cardinal Health announced plans to open a new, modernized distribution center in Walton Hills, Ohio, supporting its Global Medical Products and Distribution business, in spring 2025
Cardinal Health was ranked 17th on World’s Best Companies of 2024 list by TIME
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company’s customer-centric focus drives continuous improvement and leads to innovative solutions that improve people’s lives every day